SEC Fines Ex-Biotech CEO For Fertility Drug Misstatements
A former CEO of a biotech company focused on fertility treatments agreed Tuesday to pay over $119,000 to settle claims from the U.S. Securities and Exchange Commission that she misled investors...To view the full article, register now.
Already a subscriber? Click here to view full article